

ORIGINAL ARTICLE

Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma

D.F. Bajorin, J.A. Witjes, J.E. Gschwend, M. Schenker, B.P. Valderrama, Y. Tomita, A. Bamias, T. Lebrecht, S.F. Shariat, S.H. Park, D. Ye, M. Agerbaek, D. Enting, R. McDermott, P. Gajate, A. Peer, M.I. Milowsky, A. Nosov, J. Neif Antonio, Jr., K. Tupikowski, L. Toms, B.S. Fischer, A. Qureshi, S. Collette, K. Unsal-Kacmaz, E. Broughton, D. Zardavas, H.B. Koon, and M.D. Galsky

ABSTRACT

BACKGROUND

The role of adjuvant treatment in high-risk muscle-invasive urothelial carcinoma after radical surgery is not clear.

METHODS

In a phase 3, multicenter, double-blind, randomized, controlled trial, we assigned patients with muscle-invasive urothelial carcinoma who had undergone radical surgery to receive, in a 1:1 ratio, either nivolumab (240 mg intravenously) or placebo every 2 weeks for up to 1 year. Neoadjuvant cisplatin-based chemotherapy before trial entry was allowed. The primary end points were disease-free survival among all the patients (intention-to-treat population) and among patients with a tumor programmed death ligand 1 (PD-L1) expression level of 1% or more. Survival free from recurrence outside the urothelial tract was a secondary end point.

RESULTS

A total of 353 patients were assigned to receive nivolumab and 356 to receive placebo. The median disease-free survival in the intention-to-treat population was 20.8 months (95% confidence interval [CI], 16.5 to 27.6) with nivolumab and 10.8 months (95% CI, 8.3 to 13.9) with placebo. The percentage of patients who were alive and disease-free at 6 months was 74.9% with nivolumab and 60.3% with placebo (hazard ratio for disease recurrence or death, 0.70; 98.22% CI, 0.55 to 0.90; $P < 0.001$). Among patients with a PD-L1 expression level of 1% or more, the percentage of patients was 74.5% and 55.7%, respectively (hazard ratio, 0.55; 98.72% CI, 0.35 to 0.85; $P < 0.001$). The median survival free from recurrence outside the urothelial tract in the intention-to-treat population was 22.9 months (95% CI, 19.2 to 33.4) with nivolumab and 13.7 months (95% CI, 8.4 to 20.3) with placebo. The percentage of patients who were alive and free from recurrence outside the urothelial tract at 6 months was 77.0% with nivolumab and 62.7% with placebo (hazard ratio for recurrence outside the urothelial tract or death, 0.72; 95% CI, 0.59 to 0.89). Among patients with a PD-L1 expression level of 1% or more, the percentage of patients was 75.3% and 56.7%, respectively (hazard ratio, 0.55; 95% CI, 0.39 to 0.79). Treatment-related adverse events of grade 3 or higher occurred in 17.9% of the nivolumab group and 7.2% of the placebo group. Two treatment-related deaths due to pneumonitis were noted in the nivolumab group.

CONCLUSIONS

In this trial involving patients with high-risk muscle-invasive urothelial carcinoma who had undergone radical surgery, disease-free survival was longer with adjuvant nivolumab than with placebo in the intention-to-treat population and among patients with a PD-L1 expression level of 1% or more. (Funded by Bristol Myers Squibb and Ono Pharmaceutical; CheckMate 274 ClinicalTrials.gov number, NCT02632409.)

The authors' full names, academic degrees, and affiliations are listed in the Appendix. Address reprint requests to Dr. Bajorin at the Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave., New York, NY 10065, or at bajorind@mskcc.org.

N Engl J Med 2021;384:2102-14.

DOI: 10.1056/NEJMoa2034442

Copyright © 2021 Massachusetts Medical Society.

RADICAL SURGERY INVOLVING CYSTECTOMY for tumors arising in the bladder or nephroureterectomy for tumors arising in the upper urinary tract is the standard of care for patients with muscle-invasive urothelial carcinoma.^{1,2} Although radical surgery is performed with curative intent, more than 50% of patients with pathological evidence of cancer invading through the muscularis propria or involving the regional lymph nodes will have lethal metastatic recurrence.¹⁻⁴ Adjuvant chemotherapy may prolong disease-free survival among patients with locally advanced upper tract urothelial carcinoma,⁵ but no consensus has emerged regarding routine adjuvant cisplatin-based chemotherapy, and some patients with urothelial carcinoma are ineligible for or decline neoadjuvant cisplatin-based chemotherapy.^{1,2,6-9} Furthermore, despite a high risk of metastatic recurrence, no standard adjuvant systemic therapies have been shown to improve outcomes in patients with pathological evidence of residual disease after neoadjuvant cisplatin-based chemotherapy.¹⁰⁻¹²

Nivolumab is a fully human IgG4 monoclonal antibody directed against programmed death 1. At a dose of 3 mg per kilogram of body weight every 2 weeks, nivolumab has been shown to have antitumor activity in patients with metastatic urothelial carcinoma who had previously received platinum treatment¹³⁻¹⁵; it was approved in this population on the basis of the results of the CheckMate 275 trial.^{14,16,17} However, to date, no immune-checkpoint inhibitor has shown efficacy as adjuvant therapy in patients with urothelial carcinoma at high risk for metastatic recurrence after radical surgery with curative intent.^{18,19} Thus, the phase 3 CheckMate 274 trial was conducted to evaluate the efficacy and safety of adjuvant nivolumab, as compared with placebo, in patients with muscle-invasive urothelial carcinoma after radical surgery (with or without previous neoadjuvant cisplatin-based combination chemotherapy).

METHODS

PATIENTS

Eligible patients must have had radical surgery (R0, with negative surgical margins) within 120 days before randomization, with or without neoadjuvant cisplatin-based chemotherapy. Patients must have had pathological evidence of urothelial carcinoma (originating in the bladder, ureter,

or renal pelvis) with a high risk of recurrence (pathological stage of pT3, pT4a, or pN+ and patient not eligible for²⁰ or declined adjuvant cisplatin-based combination chemotherapy for patients who had not received neoadjuvant cisplatin-based chemotherapy and pathological stage of ypT2 to ypT4a or ypN+ for patients who received neoadjuvant cisplatin). Enrollment of patients with upper tract urothelial carcinomas was capped at approximately 20% to prevent substantial deviation from the natural prevalence of bladder disease as compared with upper tract disease. Eligible patients must have been disease-free as determined by means of a complete physical examination and imaging within 4 weeks before randomization, had adequate tumor tissue for biomarker analysis, and had an Eastern Cooperative Oncology Group performance-status score of 0 or 1 (on a 5-point scale, with higher scores indicating greater disability). Further details are included in the Methods section of the Supplementary Appendix, available with the full text of this article at NEJM.org.

TRIAL DESIGN AND TREATMENTS

This was a phase 3, multicenter, double-blind, randomized trial of adjuvant nivolumab as compared with placebo. Patients were assigned to the trial groups in a 1:1 ratio, with stratification according to tumor programmed death ligand 1 (PD-L1) expression level ($\geq 1\%$ vs. $< 1\%$ or indeterminate), pathological nodal status (N+ vs. N0 or NX with < 10 nodes removed vs. N0 with ≥ 10 nodes removed), and use of neoadjuvant cisplatin-based combination chemotherapy (yes vs. no). Further details are included in the Methods section of the Supplementary Appendix.

Nivolumab (240 mg) or placebo was administered every 2 weeks as a 30-minute intravenous infusion for up to 1 year or until disease recurrence or discontinuation from the trial. Dose delays or discontinuations were allowed to manage toxic effects.

END POINTS AND ASSESSMENTS

The two primary end points were disease-free survival among all the patients who underwent randomization (intention-to-treat population) and among those with a tumor PD-L1 expression level of 1% or more. Disease-free survival was defined as the time between the date of randomization and the date of first recurrence (local recurrence in the urothelial tract, local recurrence



A Quick Take
is available at
NEJM.org

outside the urothelial tract, or distant recurrence) or death. Local recurrences outside the urothelial tract were defined as any recurrence in pelvic soft tissue or involving pelvic nodes below the aortic bifurcation. Disease-free survival was also evaluated in prespecified subgroups. Disease recurrence was investigator-reported, with biopsy encouraged by the protocol (available at NEJM.org) whenever feasible and at the clinical judgment of the treating physician.

Secondary end points included survival free from recurrence outside the urothelial tract (to exclude non-life-threatening second primary urothelial cancers common in this disease), overall survival, and disease-specific survival, all in both trial populations. Survival free from recurrence outside the urothelial tract (also known as non-urothelial tract recurrence-free survival) was defined as the time between the date of randomization and the date of first local recurrence outside the urothelial tract, distant recurrence, or death. Distant metastasis-free survival, safety, side-effect profile, and health-related quality of life were among the exploratory end points. PD-L1 status was defined by the percentage of positive tumor cell membrane staining in a minimum of 100 tumor cells that could be evaluated with the use of the PD-L1 IHC 28-8 pharmDx immunohistochemical assay (Dako).

The safety analysis was performed both in the group of all randomly assigned patients who received at least one dose of nivolumab or placebo and in the group of all such patients with a PD-L1 expression level of 1% or more. Adverse events were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.²¹ Relatedness of adverse events to the trial regimen was determined by the investigators. Select adverse events (those with a potential inflammatory mechanism requiring more frequent monitoring or a specific intervention, such as immunosuppressants or endocrine-replacement therapy) were also reported.

Assessments of health-related quality of life were completed with the use of the European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30), a 30-item instrument comprising six functional scales,²² and the EuroQol Group 5-Dimension 3-Level questionnaire (EQ-5D-3L).²³ Detailed definitions of end points and assess-

ments are provided in the Methods section of the Supplementary Appendix.

TRIAL OVERSIGHT

This trial was approved by the institutional review boards at the participating institutions and conducted in accordance with Good Clinical Practice guidelines as defined by the International Council for Harmonisation. All the patients provided written informed consent adhering to Declaration of Helsinki principles. A data monitoring committee provided oversight of safety and efficacy considerations. The trial was designed by the authors in collaboration with Bristol Myers Squibb. The authors vouch for the completeness and accuracy of the data and for the adherence of the trial to the protocol. The authors, with the assistance of a medical writer employed by Bristol Myers Squibb, drafted and provided final approval of the manuscript that was submitted.

STATISTICAL ANALYSIS

The sample size of approximately 700 patients was based on the between-group comparisons of the primary end points. We calculated that approximately 410 events of disease recurrence or death in the intention-to-treat population would provide approximately 87% power to detect an average hazard ratio of 0.72 with an overall type I error of 2.5% (two-sided). In patients with a PD-L1 expression level of 1% or more, approximately 162 events of disease recurrence or death would provide approximately 80% power to detect an average hazard ratio of 0.61 with an overall type I error of 2.5% (two-sided).

One interim analysis was planned to be performed when 85% of events of disease recurrence or death in each trial population had been observed (348 events in the intention-to-treat population and 137 in the group of patients with a PD-L1 expression level of $\geq 1\%$). The alpha level (0.01784 for the intention-to-treat population and 0.01282 for the group of patients with a PD-L1 expression level of $\geq 1\%$) for disease-free survival was adjusted for the planned interim analysis with the use of a Lan-DeMets alpha spending function with the O'Brien-Fleming type of boundary²⁴ in East software, version 6 (Cytel).

Disease-free survival was compared between the nivolumab and placebo groups with the use

of a two-sided stratified log-rank test. Hazard ratios and corresponding confidence intervals for disease-free survival, survival free from recurrence outside the urothelial tract, and distant metastasis-free survival were estimated with the use of a stratified Cox proportional-hazards model. The secondary end point of overall survival was planned to be formally compared with the use of a hierarchical procedure in each population and will be assessed with longer follow-up, on the basis of the number of deaths specified in the trial protocol.

Mixed-effects linear regression for repeated-measures analyses was performed with the use of the EORTC QLQ-C30 and EQ-5D-3L instruments to estimate treatment effects on each of the scores over time. The model included the covariates trial group, time, stratification factors, baseline score, interaction between baseline score and time, and interaction between trial group and time, all as fixed effects, and random intercept and random slope for the time variable. Further information regarding statistical analyses is included in the Methods section of the Supplementary Appendix.

RESULTS

PATIENTS AND TREATMENTS

Between April 2016 and January 2020, a total of 709 patients underwent randomization at 156 sites in 29 countries in North and South America, Europe, Asia, and Australia. In the intention-to-treat population, 353 patients were randomly assigned to receive nivolumab and 356 to receive placebo. The population with a PD-L1 expression level of 1% or more comprised 140 patients in the nivolumab group and 142 patients in the placebo group, as recorded at randomization by means of the interactive voice-response system (282 patients). In the intention-to-treat population, 53.3% of the patients in the nivolumab group and 56.3% of those in the placebo group discontinued the trial regimen. The most common reason for discontinuation was disease recurrence (25.6% in the nivolumab group and 42.2% in the placebo group) (Fig. S1 in the Supplementary Appendix). In the intention-to-treat population, 47.3% of the patients who received nivolumab and 47.2% of those who received placebo had resected lymph nodes with urothelial

carcinoma invasion. Previous neoadjuvant cisplatin-based combination chemotherapy was administered in 43.3% of the patients in the nivolumab group and in 43.5% of those in the placebo group. The characteristics of the patients at baseline were balanced between the two groups in the intention-to-treat population (Table 1) and in the group of patients with a PD-L1 expression level of 1% or more (Table S1).

EFFICACY

The median follow-up was 20.9 months (range, 0.1 to 48.3) among patients who received nivolumab and 19.5 months (range, 0 to 50.0) among those who received placebo (minimum follow-up, 5.9 months). The median disease-free survival was 20.8 months (95% confidence interval [CI], 16.5 to 27.6) in the nivolumab group and 10.8 months (95% CI, 8.3 to 13.9) in the placebo group in the intention-to-treat population. The percentage of patients who were alive and disease-free at 6 months was 74.9% with nivolumab and 60.3% with placebo in the intention-to-treat population (hazard ratio for disease recurrence or death, 0.70; 98.22% CI, 0.55 to 0.90; $P < 0.001$) (Fig. 1A). Among patients with a PD-L1 expression level of 1% or more, the percentage who were alive and disease-free at 6 months was 74.5% with nivolumab and 55.7% with placebo (hazard ratio, 0.55; 98.72% CI, 0.35 to 0.85; $P < 0.001$) (Fig. 1B).

The subgroup analysis is shown in Figure 2. A higher probability of disease-free survival with nivolumab than with placebo was observed regardless of nodal status, PD-L1 status, or use or nonuse of previous neoadjuvant cisplatin-based chemotherapy. A total of 83.6% of the patients with censored data in the entire trial population were still receiving nivolumab or placebo or were in follow-up at the time of the database lock (August 27, 2020) (Table S2).


In the intention-to-treat population, the median survival free from recurrence outside the urothelial tract was 22.9 months (95% CI, 19.2 to 33.4) among patients who received nivolumab and 13.7 months (95% CI, 8.4 to 20.3) among those who received placebo. The percentage of patients who were alive and free from recurrence outside the urothelial tract at 6 months was 77.0% with nivolumab and 62.7% with placebo (hazard ratio for recurrence outside the urothe-

Table 1. Demographic and Clinical Characteristics of the Patients at Baseline.*		
Characteristic	Nivolumab (N = 353)	Placebo (N = 356)
Age		
Mean (range) — yr	65.3 (30–92)	65.9 (42–88)
<65 yr — no. (%)	155 (43.9)	136 (38.2)
≥65 yr — no. (%)	198 (56.1)	220 (61.8)
Sex — no. (%)		
Male	265 (75.1)	275 (77.2)
Female	88 (24.9)	81 (22.8)
Race or ethnic group — no. (%)†		
White	264 (74.8)	272 (76.4)
Asian	80 (22.7)	75 (21.1)
Black	2 (0.6)	3 (0.8)
American Indian or Alaska Native	1 (0.3)	0
Other	6 (1.7)	5 (1.4)
Not reported	0	1 (0.3)
ECOG performance-status score — no. (%)‡		
0	224 (63.5)	221 (62.1)
1	122 (34.6)	125 (35.1)
2	7 (2.0)	9 (2.5)
Not reported	0	1 (0.3)
Tumor origin at initial diagnosis — no. (%)		
Urinary bladder	279 (79.0)	281 (78.9)
Renal pelvis	44 (12.5)	52 (14.6)
Ureter	30 (8.5)	23 (6.5)
Time from initial diagnosis to randomization — no. (%)		
<1 yr	325 (92.1)	324 (91.0)
≥1 yr	28 (7.9)	32 (9.0)
PD-L1 expression level of ≥1% by IVRS — no. (%)		
	140 (39.7)	142 (39.9)
Previous neoadjuvant cisplatin therapy — no. (%)		
	153 (43.3)	155 (43.5)
Pathological tumor stage and nodal status at resection — no. (%)§		
pT2N–	25 (7.1)	29 (8.1)
pT3,4N–	158 (44.8)	159 (44.7)
pT0–4N1	71 (20.1)	72 (20.2)
pT0–4N2,3	96 (27.2)	96 (27.0)
pTisN–	1 (0.3)	0
Not reported	2 (0.6)	0
Pathological tumor stage at resection — no. (%)¶		
pTX	5 (1.4)	0
pT0	5 (1.4)	7 (2.0)
pTis	4 (1.1)	3 (0.8)
pT1	13 (3.7)	14 (3.9)
pT2	62 (17.6)	65 (18.3)
pT3	206 (58.4)	204 (57.3)
pT4a	57 (16.1)	62 (17.4)
Not reported	1 (0.3)	1 (0.3)
Nodal status at resection — no. (%)		
N0 or NX with <10 nodes removed	94 (26.6)	99 (27.8)

Table 1. (Continued.)

Characteristic	Nivolumab (N=353)	Placebo (N=356)
N0 with ≥10 nodes removed	91 (25.8)	88 (24.7)
N1	71 (20.1)	72 (20.2)
N2	84 (23.8)	76 (21.3)
N3	12 (3.4)	20 (5.6)
Not reported	1 (0.3)	1 (0.3)

* Percentages may not total 100 because of rounding. IVRS denotes interactive voice-response system, and PD-L1 programmed death ligand 1.
 † Race or ethnic group was reported by the patient.
 ‡ Eastern Cooperative Oncology Group (ECOG) performance-status scores range from 0 to 5, with higher scores indicating greater disability.
 § This was not a prespecified subgroup. Patients with pT2N– disease were eligible only if they received neoadjuvant cisplatin-based chemotherapy. N– includes N0 and NX, and T0 includes pTX, pT0, and pTis.
 ¶ The pathological tumor staging included patients with any nodal status.






Figure 2 (facing page). Disease-free Survival According to Subgroups in the Intention-to-Treat Population.

The hazard ratio was not computed for categories with fewer than 10 patients per trial group (denoted by NA [not applicable]). Confidence intervals are not adjusted for multiplicity. Arrows indicate that the limits of the confidence interval are not shown. Race or ethnic group was reported by the patient. Eastern Cooperative Oncology Group (ECOG) performance-status scores range from 0 to 5, with higher scores indicating greater disability. Combined pathological tumor stage and nodal status was not a prespecified subgroup. Patients with pT2N- disease were eligible only if they received neoadjuvant cisplatin-based chemotherapy. For the combination of tumor stage and nodal status, N- includes N0 and NX, and T0 includes pTX, pT0, and pTis. Previous chemotherapy regimens that were received by patients in the trial included carboplatin, cisplatin, cisplatin-doxorubicin-methotrexate-vinblastine, cisplatin-gemcitabine, doxorubicin, epirubicin, fluorouracil, gemcitabine, investigational agent, methotrexate, paclitaxel, tuberculin, vinblastine, and vincristine.

lial tract or death, 0.72; 95% CI, 0.59 to 0.89) (Fig. 3A). Among patients with a PD-L1 expression level of 1% or more, the percentage who were alive and free from recurrence outside the urothelial tract at 6 months was 75.3% with nivolumab and 56.7% with placebo (hazard ratio, 0.55; 95% CI, 0.39 to 0.79) (Fig. 3B).

Distant metastasis-free survival was also longer with nivolumab than with placebo in both trial populations. In the intention-to-treat population, the median distant metastasis-free survival was 40.5 months (95% CI, 22.4 to could not be estimated) among patients who received nivolumab and 29.5 months (95% CI, 16.7 to could not be estimated) among those who received placebo. The percentage of patients who were alive and free from distant metastasis at 6 months was 82.5% with nivolumab and 69.8% with placebo (hazard ratio for distant metastasis or death, 0.75; 95% CI, 0.59 to 0.94) (Fig. S2A). Among patients with a PD-L1 expression level of 1% or more, the percentage who were alive and free from distant metastasis at 6 months was 78.7% with nivolumab and 65.7% with placebo (hazard ratio, 0.61; 95% CI, 0.42 to 0.90) (Fig. S2B).

EXPOSURE AND SAFETY

A total of 351 patients in the nivolumab group and 348 in the placebo group received at least one dose of the trial regimen. The median duration of exposure was 8.8 months (range, 0 to 12.5)

in the nivolumab group and 8.2 months (range, 0 to 12.6) in the placebo group.


Adverse events of any cause occurred in 98.9% of the patients in the nivolumab group and 95.4% of those in the placebo group; events of grade 3 or higher occurred in 42.7% and 36.8% of the patients in the respective groups. Treatment-related adverse events of any grade occurred in 77.5% of the patients in the nivolumab group and 55.5% of those in the placebo group; events of grade 3 or higher occurred in 17.9% and 7.2% of the patients in the respective groups (Table 2). The most common treatment-related adverse events of any grade in the nivolumab group were pruritus (23.1%), fatigue (17.4%), and diarrhea (16.8%). The most common treatment-related adverse events of grade 3 or higher in the nivolumab group were elevations in the serum levels of lipase (5.1%) and amylase (3.7%) as well as diarrhea (0.9%), colitis (0.9%), and pneumonitis (0.9%). Treatment-related select adverse events (i.e., those events with a potential inflammatory mechanism requiring more frequent monitoring or a specific intervention, such as immunosuppressants or endocrine-replacement therapy) are summarized in Table S3. The safety profile of nivolumab was similar in patients with a PD-L1 expression level of 1% or more (data not shown).

Treatment-related deaths due to pneumonitis occurred in two patients in the nivolumab group. Both patients began glucocorticoid treatment at the onset of pneumonitis; one patient began 3 days after the last dose of trial therapy, and the other began 16 days after the last dose of trial therapy.

Treatment-related adverse events of any grade that led to discontinuation of the trial regimen occurred in 12.8% of the patients in the nivolumab group and 2.0% of those in the placebo group. The most frequent treatment-related adverse events leading to discontinuation of nivolumab were pneumonitis (1.7%), rash (1.1%), colitis (0.9%), and an increased alanine aminotransferase level (0.9%).

QUALITY OF LIFE

The percentage of patients who completed the EORTC QLQ-C30 was 85% or greater during the treatment period and 75% or greater in the follow-up period. Changes from baseline in the EORTC QLQ-C30 global health status score and



the EQ-5D-3L visual analogue scale score over time indicated that there was no meaningful difference in deterioration in quality of life between patients who received nivolumab and those who received placebo, both in the intention-to-treat population and in patients with a PD-L1 expression level of 1% or more (Figs. S3 and S4).

DISCUSSION

Among patients with high-risk muscle-invasive urothelial carcinoma who had undergone radical

surgery, disease-free survival was significantly longer with adjuvant nivolumab than with placebo, both in the intention-to-treat population and among patients with a tumor PD-L1 expression level of 1% or more. In the intention-to-treat population, the median disease-free survival with nivolumab was nearly double that with placebo (20.8 months vs. 10.8 months). Survival free from recurrence outside the urothelial tract and distant metastasis-free survival were also longer with nivolumab than with placebo in both trial populations.

Table 2. Adverse Events.*

Adverse Event	Nivolumab (N=351)		Placebo (N=348)	
	Any Grade	Grade ≥3	Any Grade	Grade ≥3
	<i>number of patients (percent)</i>			
Adverse event of any cause	347 (98.9)	150 (42.7)	332 (95.4)	128 (36.8)
Adverse event related to nivolumab or placebo†	272 (77.5)	63 (17.9)	193 (55.5)	25 (7.2)
Pruritus	81 (23.1)	0	40 (11.5)	0
Fatigue	61 (17.4)	1 (0.3)	42 (12.1)	0
Diarrhea	59 (16.8)	3 (0.9)	38 (10.9)	1 (0.3)
Rash	53 (15.1)	2 (0.6)	19 (5.5)	0
Increased lipase level	34 (9.7)	18 (5.1)	20 (5.7)	9 (2.6)
Hypothyroidism	34 (9.7)	0	5 (1.4)	0
Increased amylase level	33 (9.4)	13 (3.7)	20 (5.7)	5 (1.4)
Hyperthyroidism	33 (9.4)	0	3 (0.9)	0
Asthenia	24 (6.8)	2 (0.6)	17 (4.9)	0
Nausea	24 (6.8)	0	13 (3.7)	0
Decreased appetite	20 (5.7)	2 (0.6)	11 (3.2)	0
Increased blood creatinine level	20 (5.7)	1 (0.3)	11 (3.2)	0
Maculopapular rash	19 (5.4)	2 (0.6)	4 (1.1)	0

* Shown are events that were reported between the first dose and 30 days after the last dose of nivolumab or placebo.

† Shown are events that occurred in at least 5% of the patients in either trial group. There were two treatment-related deaths due to pneumonitis in the nivolumab group.

The safety profile of nivolumab monotherapy was consistent with that in previous trials involving patients with metastatic urothelial carcinoma and other cancers.^{13,14,25} Both treatment-related adverse events of grade 3 or higher and treatment-related adverse events leading to discontinuation of the trial regimen occurred in less than 18% of the patients who received nivolumab and in less than 8% of those who received placebo. The favorable efficacy and safety results are supported by EORTC QLQ-C30 and EQ-5D-3L results that showed no deterioration in health-related quality of life over time in patients who received nivolumab as compared with those who received placebo. Two treatment-related deaths due to pneumonitis occurred in the nivolumab group.

On the basis of CheckMate 274 results, nivolumab improved clinical outcomes when administered as adjuvant therapy to patients with urothelial carcinoma at high risk for local and metastatic recurrence after surgery. In contrast, a previously reported phase 3 trial (IMvigor010

that compared adjuvant atezolizumab, an anti-PD-L1 antibody, with observation in a similar population of patients with high-risk muscle-invasive urothelial carcinoma who had undergone surgery did not show a significant difference in disease-free survival.¹⁹ Explanations for the outcome differences between the IMvigor010 and CheckMate 274 trials would be speculative.

Patients with completely resected, high-risk urothelial cancer (defined as residual cancer ≥pT2 or pN+ after neoadjuvant cisplatin-based chemotherapy or ≥pT3 or pN+ without previous chemotherapy) frequently have recurrence and have a 5-year survival of 60% or less.^{4,26,27} Although adjuvant cisplatin-based chemotherapy may improve outcomes after definitive surgery in patients eligible for cisplatin who have not received neoadjuvant chemotherapy, no previous adjuvant systemic therapies have been shown to improve outcomes in patients not eligible for cisplatin or in those with pathological evidence of residual disease despite neoadjuvant cisplatin-based chemotherapy.² These initial results from

CheckMate 274 show that adjuvant nivolumab extends disease-free survival for these patients and thus may affect clinical decision making in this context.

A subgroup analysis of disease-free survival was completed. This analysis reveals the possibility of a larger effect size in patients with bladder urothelial carcinoma than in those with renal pelvic and ureteral tumors as well as a larger effect size in patients previously treated with neoadjuvant chemotherapy than in those who had not received neoadjuvant chemotherapy; however, the trial was designed to assess the efficacy of nivolumab as compared with placebo in the entire trial population. These observations should be considered hypothesis-generating; subsequent translational analyses are planned to further interrogate these and other patient subgroups.

This interim analysis is limited by the short duration of follow-up; however, at a median follow-up of approximately 20 months, 48.2% of the patients in the nivolumab group and 57.3% of those in the placebo group had already had disease recurrence or had died. Data for certain secondary and exploratory end points, including overall survival, are to follow in accordance with the statistical analysis plan and may provide greater insight into the efficacy of nivolumab in this context. Previous studies have indicated that disease-free survival at 2 or 3 years is highly correlated with overall survival among patients with muscle-invasive urothelial carcinoma.²⁸⁻³² In addition, the trial is limited by the relatively small number of enrolled patients from underrepresented minorities.

Disease-free survival was significantly longer with adjuvant nivolumab than with placebo among patients with high-risk muscle-invasive urothelial carcinoma after radical surgery with curative intent. Further follow-up is planned to assess overall survival. Nivolumab monotherapy was associated with the expected level of toxicity, and no deterioration in quality of life was observed relative to placebo. The CheckMate 274 trial showed a significant and clinically meaningful benefit of adjuvant systemic immunotherapy as compared with placebo, both in the intention-to-treat population and in patients with a PD-L1 expression level of 1% or more.

Supported by Bristol Myers Squibb in collaboration with Ono Pharmaceutical. Dr. Bajorin is supported by a grant from the

National Institutes of Health (P30 CA008748). The authors received no financial support or compensation for publication of this manuscript.

Dr. Bajorin reports receiving consulting fees from Bristol Myers Squibb, Fidia Pharma USA, and Merck; Dr. Witjes, receiving lecture fees from Astellas Pharma and consulting fees from AstraZeneca, Bristol Myers Squibb, Ferring Pharmaceuticals, Ipsen Biopharmaceuticals, Janssen Biotech, Merck, and Sanofi Pasteur; Dr. Gschwend, receiving advisory board fees from Bristol Myers Squibb; Dr. Schenker, receiving grant support from AbbVie, Amgen, Astellas Pharma, AstraZeneca, Bayer Healthcare, Bristol Myers Squibb, Celgene, Clovis Oncology, Eli Lilly, F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Merck, Merck Sharp and Dohme, Mylan, Novartis, Pfizer, Regeneron Pharmaceuticals, and Tesaro; Dr. Valderrama, receiving lecture fees, consulting fees, and travel support from Astellas Pharma and Bristol Myers Squibb, lecture fees and consulting fees from Bayer Healthcare and EUSA Pharma, consulting fees and travel support from F. Hoffmann-La Roche, Ipsen Biopharmaceuticals, and Pfizer, consulting fees from Merck, Merck Sharp and Dohme, Novartis Pharma, Pierre Fabre Pharmaceuticals, and Sanofi-Aventis, and lecture fees from Roche; Dr. Tomita, receiving grant support and lecture fees from Astellas Pharma and Takeda Pharmaceutical, lecture fees from Bristol Myers Squibb, Novartis Pharma, and Pfizer, grant support from Chugai Pharmaceutical, and grant support, lecture fees, and consulting fees from Ono Pharmaceutical; Dr. Bamias, receiving grant support, paid to Hellenic Genitourinary Cancer Group, advisory board fees, and lecture fees from Bristol Myers Squibb, grant support, paid to National and Kapodistrian University of Athens, lecture fees, steering committee fees, and advisory board fees from F. Hoffmann-La Roche, advisory board fees and lecture fees from Ipsen Pharma and Merck Sharp and Dohme, grant support, paid to National and Kapodistrian University of Athens, from Janssen, and grant support, paid to Hellenic Genitourinary Cancer Group, from Pfizer; Dr. Leuret, receiving travel support from Astellas Pharma, consulting fees from AstraZeneca, Ferring Pharmaceuticals, and Ipsen Fund, and advisory board fees from Bayer Healthcare and Bristol Myers Squibb; Dr. Shariat, receiving advisory board fees, lecture fees, and travel support from Astellas Pharma and advisory board fees and lecture fees from AstraZeneca, Bayer, Bristol Myers Squibb, Cepheid, Ferring Pharmaceuticals, Ipsen Biopharm, Janssen Biotech, Merck, Merck Sharp and Dohme, Olympus Therapeutics, Pierre Fabre Pharmaceuticals, Richard Wolf Medical Instruments, Roche Products, and Sanofi Pasteur; Dr. Enting, receiving travel support from Janssen Biotech, Merck, and Pfizer; Dr. McDermott, receiving advisory board fees from Astellas Pharma, Bayer, Bristol Myers Squibb, Clovis Oncology, F. Hoffmann-La Roche, Ipsen Biopharm, Janssen Biotech, Merck, and Pfizer and clinical trial fees from Regeneron Pharmaceuticals; Dr. Gajate, receiving lecture fees from Bristol Myers Squibb and Pfizer and lecture fees and advisory board fees from Roche; Dr. Peer, receiving consulting fees and lecture fees from AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, F. Hoffmann-La Roche, Merck Sharp and Dohme, and Pfizer; Dr. Milowsky, receiving consulting fees, paid to his institution, from Asieris Pharmaceuticals and serving as a clinical trial investigator for Acerta Pharma, Astellas Pharma, Bristol Myers Squibb, Clovis Oncology, Constellation Pharmaceuticals, Genentech, Incyte, Innocrin, Inovio Pharmaceuticals, Johnson & Johnson Healthcare Systems, Merck, Mirati Therapeutics, Pfizer, Roche, Seagen, Syndax Pharmaceuticals, and X4 Pharmaceuticals; Drs. Toms and Fischer, being employed by and owning stock in Bristol Myers Squibb; Dr. Qureshi, being employed by Bristol Myers Squibb; Ms. Collette and Drs. Unsal-Kacmaz, Broughton, Zardavas, and Koon, being employed by and owning stock options in Bristol Myers Squibb; and Dr. Galsky, receiving consulting fees from Astellas Pharma, Basilea, Bristol Myers Squibb, Dracen Pharmaceuticals, Dragonfly Therapeutics,

Genentech, GlaxoSmithKline, Incyte, Janssen Biotech, Merck, Numab Therapeutics, Pfizer, Rappta Therapeutics, and Seattle Genetics and advisory board fees from AstraZeneca. No other potential conflict of interest relevant to this article was reported.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

A data sharing statement provided by the authors is available with the full text of this article at NEJM.org.

We thank the patients and their families for making this trial possible; the staff of Dako, an Agilent Technologies company, for collaborative development of the PD-L1 IHC 28-8 pharmDx assay; Alex Azrilevich, Pharm.D., who contributed to the trial concept and design; Benedicte Marchal, M.Sc., who served as the protocol manager for the trial; and Nicolette Belletier, Ph.D., of Parexel, who was supported by the sponsor for professional medical writing assistance with an earlier version of the manuscript.

APPENDIX

The authors' full names and academic degrees are as follows: Dean F. Bajorin, M.D., J. Alfred Witjes, M.D., Jürgen E. Gschwend, M.D., Michael Schenker, M.D., Begoña P. Valderrama, M.D., Yoshihiko Tomita, M.D., Ph.D., Aristotelis Bamias, M.D., Thierry Lebret, M.D., Shahrokh F. Shariat, M.D., Se Hoon Park, M.D., Dingwei Ye, M.D., Mads Agerbaek, M.D., Deborah Enting, M.D., Ray McDermott, M.D., Pablo Gajate, M.D., Avivit Peer, M.D., Matthew I. Milowsky, M.D., Alexander Nosov, M.D., João Neif Antonio, Jr., M.D., Krzysztof Tupikowski, M.D., Laurence Toms, B.M., B.Ch., Bruce S. Fischer, M.D., Anila Qureshi, M.D., Sandra Collette, M.Sc., Keziban Unsalkacmaz, Ph.D., Edward Broughton, Ph.D., Dimitrios Zardavas, M.D., Henry B. Koon, M.D., and Matthew D. Galsky, M.D.

The authors' affiliations are as follows: the Memorial Sloan Kettering Cancer Center (D.F.B.), Weill Cornell Medical College (S.F.S.), and Icahn School of Medicine at Mount Sinai (M.D.G.) — all in New York; Radboud University, Nijmegen, the Netherlands (J.A.W.); the Department of Urology, Technical University Munich, Munich, Germany (J.E.G.); Nectarie Oncology Center, Craiova, Romania (M.S.); Hospital Universitario Virgen del Rocío, Seville (B.P.V.), and Ramon y Cajal University Hospital, Madrid (P.G.) — both in Spain; Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan (Y.T.); National and Kapodistrian University of Athens, Athens (A.B.); the Urology Department, Hôpital Foch, Université Paris-Saclay, Université Versailles Saint-Quentin-en-Yvelines, Versailles, France (T.L.); Medical University of Vienna, Vienna General Hospital, Vienna (S.F.S.); University of Texas Southwestern Medical Center, Dallas (S.F.S.); Charles University, Prague, Czech Republic (S.F.S.); the Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow (S.F.S.), and Federal State Budget Institution N.N. Petrov National Medical Research Center of Oncology of the Ministry of Health Care of the Russian Federation, St. Petersburg (A.N.) — both in Russia; Sungkyunkwan University Samsung Medical Center, Seoul, South Korea (S.H.P.); Fudan University Shanghai Cancer Center, Shanghai, China (D.Y.); Aarhus University Hospital, Aarhus, Denmark (M.A.); Guy's and St. Thomas' NHS Foundation Trust, London (D.E.); St. Vincent's University Hospital and Cancer Trials Ireland, Dublin (R.M.); Rambam Health Care Campus, Haifa, Israel (A.P.); University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill (M.I.M.); Hospital de Amor de Barretos—Pio XII Foundation, Barretos, Brazil (J.N.A.); the Subdivision of Urology, Wrocław Comprehensive Cancer Center, Wrocław, Poland (K.T.); and Bristol Myers Squibb, Princeton, NJ (L.T., B.S.F., A.Q., S.C., K.U.-K., E.B., D.Z., H.B.K.).

REFERENCES

- Alfred Witjes J, Lebret T, Compérat EM, et al. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. *Eur Urol* 2017;71:462-75.
- National Comprehensive Cancer Network. Bladder cancer version 6. 2020 (https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf).
- Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2020 update. *Eur Urol* 2021; 79:62-79.
- Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. *J Clin Oncol* 2001;19: 666-75.
- Birtle A, Johnson M, Chester J, et al. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. *Lancet* 2020;395:1268-77.
- Dash A, Galsky MD, Vickers AJ, et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. *Cancer* 2006;107:506-13.
- Necchi A, Lo Vullo S, Mariani L, et al. Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urology-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration. *BJU Int* 2018;121:252-9.
- Xylinas E, Rink M, Margulis V, et al. Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy. *BJU Int* 2013;112:453-61.
- Donat SM, Shabsigh A, Savage C, et al. Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. *Eur Urol* 2009;55: 177-85.
- Sternberg CN, Skoneczna I, Kerst JM, et al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. *Lancet Oncol* 2015;16:76-86.
- Cognetti F, Ruggeri EM, Felici A, et al. Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. *Ann Oncol* 2012;23: 695-700.
- Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. *Eur Urol* 2005;48:189-99.
- Sharma P, Callahan MK, Bono P, et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. *Lancet Oncol* 2016;17:1590-8.
- Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. *Lancet Oncol* 2017;18:312-22.
- Sharma P, Siefker-Radtke A, de Braud F, et al. Nivolumab alone and with ipilimumab in previously treated metastatic urothelial carcinoma: CheckMate 032 nivolumab 1 mg/kg plus ipilimumab 3 mg/kg expansion cohort results. *J Clin Oncol* 2019;37:1608-16.
- Opdivo (nivolumab) [package insert]. Princeton, NJ: Bristol Myers Squibb, 2020.
- European Medicines Agency. Summary of product characteristics (https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf).
- Kim HS, Seo HK. Immune checkpoint inhibitors for urothelial carcinoma. *Investig Clin Urol* 2018;59:285-96.

19. Bellmunt J, Hussain M, Gschwend JE, et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol* 2021;22:525-37.
20. Galsky MD, Hahn NM, Rosenberg J, et al. Treatment of patients with metastatic urothelial cancer "unfit" for cisplatin-based chemotherapy. *J Clin Oncol* 2011;29:2432-8.
21. Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. National Cancer Institute, June 14, 2010 (https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40).
22. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. *J Natl Cancer Inst* 1993;85:365-76.
23. EuroQol Group. EuroQol — a new facility for the measurement of health-related quality of life. *Health Policy* 1990;16:199-208.
24. Lan GKK, Demets DL. Discrete sequential boundaries for clinical trials. *Biometrika* 1983;70:659-63.
25. Motzer RJ, Escudier B, McDermott DE, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. *N Engl J Med* 2015;373:1803-13.
26. Pradère B, Thibault C, Vetterlein MW, et al. Peri-operative chemotherapy for muscle-invasive bladder cancer: status-quo in 2017. *Transl Androl Urol* 2017;6:1049-59.
27. Shariat SF, Karakiewicz PI, Palapattu GS, et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. *J Urol* 2006;176:2414-22.
28. Fajkovic H, Cha EK, Xylinas E, et al. Disease-free survival as a surrogate for overall survival in upper tract urothelial carcinoma. *World J Urol* 2013;31:5-11.
29. Sonpavde G, Khan MM, Lerner SP, et al. Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer. *J Urol* 2011;185:456-61.
30. Kim HS, Jeong CW, Kwak C, Kim HH, Ku JH. Disease-free survival at 2 and 3 years is a significant early surrogate marker predicting the 5-year overall survival in patients treated with radical cystectomy for urothelial carcinoma of the bladder: external evaluation and validation in a cohort of Korean patients. *Front Oncol* 2015;5:246.
31. Rink M, Lee DJ, Kent M, et al. Predictors of cancer-specific mortality after disease recurrence following radical cystectomy. *BJU Int* 2013;111:E30-E36.
32. Rink M, Sjöberg D, Comploj E, et al. Risk of cancer-specific mortality following recurrence after radical nephroureterectomy. *Ann Surg Oncol* 2012;19:4337-44.

Copyright © 2021 Massachusetts Medical Society.

NEJM WEEKLY CME

Beginning July 1, 2021, NEJM Weekly CME activities will no longer be featured in print issues, but they will continue to be published online at [NEJM.org/continuing-medical-education](https://www.nejm.org/continuing-medical-education).